Cancer genetics · 2026
Outcomes of TSHR mutations in indeterminate thyroid nodules.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Magri Angela, Savoia Gianluca, Rutenberg Nicholas J, Avior Galit, Zarruk Alexandro, da Silva Wurzba Sabrina Daniela, Payne Richard J, Forest Véronique-Isabelle
Аннотация
BACKGROUND: The thyrotropin receptor (TSHR) mutation can be present in autonomously functioning thyroid nodules (AFTNs). Our objective was to evaluate whether patients with a TSHR mutation developed AFTNs and to assess the impact of this mutation on thyroid malignancy.
METHODS: We conducted a multicenter retrospective study of 1211 patients from Montreal, Canada, and from Tel Aviv, Israel, who underwent molecular testing (ThyroseqV3®) from January 2018 to December 2022 following an indeterminate cytology result (Bethesda III-IV). All TSHR-positive patients (n = 56) and 90 randomly selected mutation-negative patients were included. TSH levels were measured at least twice over 1-3 years following molecular testing.
RESULTS: The case group was predominantly female (94.8%) with a mean age of 51.2 years. The mean TSH levels in the control and case groups were 2.29 (CI=95% 1.93-2.66) and 1.55 (CI=95% 1.23-1.86) at first follow-up, and 2.17 (CI=95% 1.80-2.54) and 1.33 (CI=95% 1.01-1.66) at second follow-up. Higher allele frequency correlated with lower TSH levels (P = 0.005, P = 0.002). All isolated TSHR mutations were associated with benignity regardless of allele frequency, while co-occurring genetic alterations were associated with malignant outcomes.
CONCLUSIONS: TSHR mutations are generally benign and correlate with lower TSH levels. Co-mutations may influence thyroid function and malignancy risk.
METHODS: We conducted a multicenter retrospective study of 1211 patients from Montreal, Canada, and from Tel Aviv, Israel, who underwent molecular testing (ThyroseqV3®) from January 2018 to December 2022 following an indeterminate cytology result (Bethesda III-IV). All TSHR-positive patients (n = 56) and 90 randomly selected mutation-negative patients were included. TSH levels were measured at least twice over 1-3 years following molecular testing.
RESULTS: The case group was predominantly female (94.8%) with a mean age of 51.2 years. The mean TSH levels in the control and case groups were 2.29 (CI=95% 1.93-2.66) and 1.55 (CI=95% 1.23-1.86) at first follow-up, and 2.17 (CI=95% 1.80-2.54) and 1.33 (CI=95% 1.01-1.66) at second follow-up. Higher allele frequency correlated with lower TSH levels (P = 0.005, P = 0.002). All isolated TSHR mutations were associated with benignity regardless of allele frequency, while co-occurring genetic alterations were associated with malignant outcomes.
CONCLUSIONS: TSHR mutations are generally benign and correlate with lower TSH levels. Co-mutations may influence thyroid function and malignancy risk.